Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Effect of Metreleptin Therapy in the Treatment of Severe Insulin Resistance

Phase 2

Active, not recruiting

Conditions: Severe Insulin Resistance

Interventions: Drug: Metreleptin

First Posted Date: 2004-06-21

Last Posted Date: 2025-01-30

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 11

Registration Number: NCT00085982

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Rebeccamycin Analog as Second-Line Therapy in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer That Relapsed After Previous First-Line Chemotherapy

Phase 2

Terminated

Conditions: Extensive Stage Small Cell Lung Cancer
Limited Stage Small Cell Lung Cancer
Recurrent Small Cell Lung Cancer

Interventions: Drug: becatecarin

First Posted Date: 2004-06-11

Last Posted Date: 2014-05-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 21

Registration Number: NCT00084487

Locations: 🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States

LMB-2 Immunotoxin in Treating Young Patients With Relapsed or Refractory Leukemia or Lymphoma

Phase 1

Completed

Conditions: Leukemia
Lymphoma

First Posted Date: 2004-06-11

Last Posted Date: 2015-04-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT00085150

Locations: 🇺🇸
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

and more 2 locations

Tipifarnib and Erlotinib Hydrochloride in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Solid Neoplasm

Interventions: Drug: Erlotinib Hydrochloride
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Tipifarnib

First Posted Date: 2004-06-11

Last Posted Date: 2018-05-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 29

Registration Number: NCT00085553

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Phase 1

Completed

Conditions: Adult Giant Cell Glioblastoma
Adult Glioblastoma
Adult Gliosarcoma

Interventions: Drug: cilengitide
Drug: temozolomide
Radiation: radiation therapy
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2004-06-11

Last Posted Date: 2016-02-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 112

Registration Number: NCT00085254

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States

and more 5 locations

Depsipeptide in Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase 2

Completed

Conditions: Stage IV Squamous Cell Carcinoma of the Larynx
Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity
Stage IV Squamous Cell Carcinoma of the Oropharynx
Stage IV Squamous Cell Carcinoma of the Hypopharynx

Interventions: Drug: romidepsin

First Posted Date: 2004-06-11

Last Posted Date: 2021-03-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 14

Registration Number: NCT00084682

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Montefiore Medical Center, Bronx, New York, United States

Erlotinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Not Applicable

Completed

Conditions: Recurrent Non-small Cell Lung Cancer
Stage IIIB Non-small Cell Lung Cancer
Stage IV Non-small Cell Lung Cancer

Interventions: Drug: erlotinib hydrochloride
Other: laboratory biomarker analysis

First Posted Date: 2004-06-11

Last Posted Date: 2014-03-31

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 129

Registration Number: NCT00085280

Locations: 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States

Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors

Phase 2

Terminated

Conditions: Gastrinoma
Glucagonoma
Insulinoma
Metastatic Gastrointestinal Carcinoid Tumor
Pancreatic Polypeptide Tumor
Pulmonary Carcinoid Tumor
Recurrent Gastrointestinal Carcinoid Tumor
Recurrent Islet Cell Carcinoma
Regional Gastrointestinal Carcinoid Tumor
Somatostatinoma

Interventions: Drug: romidepsin
Other: laboratory biomarker analysis

First Posted Date: 2004-06-11

Last Posted Date: 2013-06-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 25

Registration Number: NCT00084461

Locations: 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States

Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131

Phase 2

Completed

Conditions: Stage IVB Follicular Thyroid Cancer
Recurrent Thyroid Cancer
Stage IVC Follicular Thyroid Cancer
Stage IVC Papillary Thyroid Cancer
Stage IVA Follicular Thyroid Cancer
Stage IVA Papillary Thyroid Cancer
Stage IVB Papillary Thyroid Cancer

Interventions: Drug: Decitabine
Radiation: Iodine I 131
Biological: Recombinant thyrotropin alfa
Radiation: Fludeoxyglucose F 18
Procedure: Positron emission tomography

First Posted Date: 2004-06-11

Last Posted Date: 2018-11-29

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 12

Registration Number: NCT00085293

Locations: 🇺🇸
University of Colorado at Denver, Aurora, Colorado, United States
🇺🇸
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Decitabine and Valproic Acid in Treating Patients With Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: Recurrent Non-small Cell Lung Cancer
Stage IV Non-small Cell Lung Cancer

Interventions: Drug: decitabine
Drug: valproic acid
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2004-06-11

Last Posted Date: 2013-09-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 25

Registration Number: NCT00084981

Locations: 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy